Posts by: Alice Melão

News

Generex Biotechnology is planning a Phase 2 trial to test a combination of its AE37 peptide vaccine and Keytruda (pembrolizumab) in patients with advanced triple-negative breast cancer, after the U.S. Food and Drug ... Read more

January 4, 2019

Phase 3 Trial of Sacituzumab Govitecan Recruiting Triple-negative Breast Cancer Patients

News

A Phase 3 trial is recruiting participants to examine the effects of sacituzumab govitecan in patients with metastatic triple-negative breast cancer (TNBC) who failed to respond, or relapsed after at least ... Read more

January 2, 2019

Enrollment Complete in Phase 2 Trial of NeuVax-Herceptin for HER2-Positive, High-Risk Breast Cancer

News

The investigator-sponsored trial studying a combination of NeuVax (nelipepimut-S, NPS) and Herceptin (trastuzumab) as a maintenance treatment for HER2-positive breast cancer at high risk of recurrence has completed patient enrollment, Sellas Life ... Read more

December 10, 2018

Phase 1/2 Trial Testing Combo of Bria-IMT and Immune Checkpoint Inhibitors Begins Dosing Breast Cancer Patients

News

BriaCell Therapeutics has started patient dosing in a Phase 1/2a clinical trial testing its immunotherapy candidate Bria-IMT — used in combination with the immune checkpoint inhibitors Keytruda (pembrolizumab) or Yervoy (ipilimumab) ... Read more

December 3, 2018

Planned Phase 2 Trial to Test Vaccine in Triple-negative Breast Cancer Patients, Generex Says

News

Generex Biotechnology has entered into an agreement with the NSABP Foundation to manage a possible Phase 2 clinical trial testing an anti-cancer vaccine in patients with metastatic triple negative breast ... Read more

September 28, 2018

CrownBio Acquires Patient-derived Breast Cancer Mouse Models from University of Utah

News

CrownBio has established an agreement with the University of Utah to acquire and commercialize the university’s unique collection of patient-derived mouse models of breast cancer. The models were developed ... Read more

September 7, 2018

Health Canada Approves Perjeta Combo Therapy for Early Breast Cancer After Surgery

News

Health Canada has approved the use of Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy to prevent the recurrence of early breast cancer after surgery. The combination is ... Read more

August 29, 2018August 29, 2018

A Primary Breast Cancer Tumor Can Inhibit Cancer Cells from Forming Secondary Tumors, Mice Study Shows

News

Some types of breast cancers can prevent the development of secondary tumors elsewhere in the body, a process known as metastasis, through an immune-mediated inflammatory mechanism, an international research ... Read more

August 10, 2018

FDA Approves Non-radioactive Tracer Able to Detect Lymph Nodes Affected by Breast Cancer

News

The U.S. Food and Drug Administration (FDA) approved the non-radioactive tracer Magtrace for the pre-surgical detection of lymph nodes affected by breast cancer. Used in combination with Sentimag Magnetic ... Read more

Posts by: Alice Melão

Alice Melão

FDA OKs Phase 2 Trial of AE37-Keytruda Combo in Metastatic Triple-negative Breast Cancer

Phase 3 Trial of Sacituzumab Govitecan Recruiting Triple-negative Breast Cancer Patients

Top 10 Breast Cancer Articles of 2018

Enrollment Complete in Phase 2 Trial of NeuVax-Herceptin for HER2-Positive, High-Risk Breast Cancer

Phase 1/2 Trial Testing Combo of Bria-IMT and Immune Checkpoint Inhibitors Begins Dosing Breast Cancer Patients

Planned Phase 2 Trial to Test Vaccine in Triple-negative Breast Cancer Patients, Generex Says

CrownBio Acquires Patient-derived Breast Cancer Mouse Models from University of Utah

Health Canada Approves Perjeta Combo Therapy for Early Breast Cancer After Surgery

A Primary Breast Cancer Tumor Can Inhibit Cancer Cells from Forming Secondary Tumors, Mice Study Shows

FDA Approves Non-radioactive Tracer Able to Detect Lymph Nodes Affected by Breast Cancer

Pin It on Pinterest